ViroMissile, Inc.
ViroMissile is developing the world’s first truly intravenously-delivered viruses that target and kill tumors.
Funding history
About ViroMissile, Inc.
How much funding has ViroMissile, Inc. raised?
ViroMissile, Inc. has raised $800K in total funding. The most recent round was Seed.
Where is ViroMissile, Inc. headquartered?
ViroMissile, Inc. is headquartered in La Jolla, CA.
What does ViroMissile, Inc. do?
ViroMissile is developing the world’s first truly intravenously-delivered viruses that target and kill tumors.
What problem does ViroMissile, Inc. solve?
Traditional cancer drug development spends years and hundreds of millions of dollars targeting one driver of one cancer type, and therapies often can't reach every tumor in cases of metastatic disease.
What's ViroMissile, Inc.'s solution?
ViroMissile developed a proprietary strain of vaccinia virus that survives in the bloodstream, allowing it to be delivered intravenously and travel systemically to infect and destroy tumor cells while sparing healthy tissue.
What makes ViroMissile, Inc. different?
The company states it is the first to achieve successful, effective intravenous delivery of an oncolytic virus directly to tumors in humans, using a virus strain that survives in blood unlike any other in development, and was awarded 'Top Cancer Destroying Platform' (2025) by Life Sciences Review.
What makes ViroMissile, Inc. notable?
ViroMissile was founded by Dr. Nanhai George Chen and is developing IV-delivered oncolytic viruses designed to target cancer, work that has drawn industry recognition including a 'Top Cancer Destroying Platform' award.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.